WO2016063265A3 - Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos - Google Patents

Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos Download PDF

Info

Publication number
WO2016063265A3
WO2016063265A3 PCT/IB2015/058245 IB2015058245W WO2016063265A3 WO 2016063265 A3 WO2016063265 A3 WO 2016063265A3 IB 2015058245 W IB2015058245 W IB 2015058245W WO 2016063265 A3 WO2016063265 A3 WO 2016063265A3
Authority
WO
WIPO (PCT)
Prior art keywords
skin
treating
infections
mucosae
bromelain
Prior art date
Application number
PCT/IB2015/058245
Other languages
English (en)
French (fr)
Other versions
WO2016063265A2 (pt
Inventor
Rita Manuela PALMEIRA DE OLIVEIRA
Ana Cristina PALMEIRA DE OLIVEIRA
Original Assignee
Palmeira De Oliveira Rita Manuela
Palmeira De Oliveira Ana Cristina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palmeira De Oliveira Rita Manuela, Palmeira De Oliveira Ana Cristina filed Critical Palmeira De Oliveira Rita Manuela
Priority to US15/521,403 priority Critical patent/US20170304411A1/en
Priority to EP15805257.1A priority patent/EP3210619A2/en
Publication of WO2016063265A2 publication Critical patent/WO2016063265A2/pt
Publication of WO2016063265A3 publication Critical patent/WO2016063265A3/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A presente divulgação insere-se no domínio da terapêutica de infeções na pele ou suas mucosas e diz respeito ao uso da bromelaína isolada ou com agentes antimicrobianos para inibir, reduzir ou tratar biofilmes em infeções derivadas da presença deste mecanismo de patogenicidade. Esta aplicação pretende usufruir da ação enzimática da bromelaína para destruir os biofilmes e permitir a penetração dos antifúngicos, potenciando, deste modo, a sua ação local no foco da infeção, tratando e reduzindo os sintomas. A presente divulgação pode ser utilizada na área farmacêutica para o tratamento de infeções, em cremes, loções, géis, ou ampolas para a aplicação local na pele ou mucosas. Foram desenvolvidas formulações com capacidade de manter a estabilidade da enzima e dos restantes componentes ativos com boas características para aplicação na pele ou mucosas, em particular a vagina, promovendo, deste modo, a eficácia e a aceitabilidade do produto final.
PCT/IB2015/058245 2014-10-24 2015-10-26 Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos WO2016063265A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/521,403 US20170304411A1 (en) 2014-10-24 2015-10-26 Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
EP15805257.1A EP3210619A2 (en) 2014-10-24 2015-10-26 Topical formulation for treating skin or mucosal infections, preparation method and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT108004 2014-10-24
PT10800414 2014-10-24

Publications (2)

Publication Number Publication Date
WO2016063265A2 WO2016063265A2 (pt) 2016-04-28
WO2016063265A3 true WO2016063265A3 (pt) 2016-06-16

Family

ID=54783955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/058245 WO2016063265A2 (pt) 2014-10-24 2015-10-26 Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos

Country Status (3)

Country Link
US (1) US20170304411A1 (pt)
EP (1) EP3210619A2 (pt)
WO (1) WO2016063265A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022632A2 (pt) * 2019-05-10 2022-01-04 Locus Ip Co Llc Composições e métodos para tratar condições pulmonares relacionadas a biofilmes
JP7428842B1 (ja) 2023-03-29 2024-02-06 ａｒｔｉｅｎｃｅ株式会社 活性エネルギー線硬化型インキ、その製造方法、および印刷物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358500A1 (en) * 1988-09-08 1990-03-14 The Public Health Laboratory Service Board Method and composition for the treatment and prevention of viral infections
WO1995023614A1 (en) * 1994-03-01 1995-09-08 E.R. Squibb & Sons, Inc. Enzymatic debridement compositions and methods
US5560910A (en) * 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US20040151716A1 (en) * 2003-02-03 2004-08-05 Hamer Richard A. Material and method for treating microbial mediated dermatological conditions
US20070275045A1 (en) * 2006-02-28 2007-11-29 Evans Robin D Composition for the treatment of warts and molluscum contagiosum
US20110182874A1 (en) * 2009-11-23 2011-07-28 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
US20110243918A1 (en) * 2009-08-25 2011-10-06 Thornton Joseph P Topical medication for the treatment of hemorrhoids and method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361551A (en) * 1979-11-05 1982-11-30 Riker Laboratories, Inc. Method of enzymatic debridement
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US20050281806A1 (en) * 2004-06-16 2005-12-22 Collegium Pharmaceutical, Inc., Delaware Compositions for topical enzymatic debridement
JP5782603B2 (ja) * 2008-10-30 2015-09-24 クリーンウェル，リミティド ライアビリティ カンパニー 抗菌発泡性石鹸
US8557237B2 (en) * 2009-01-13 2013-10-15 Mindfulnessfyb, Inc. Crème comprising encapsulated bromelain for the skin, specifically for inhibiting ingrown hair
WO2012049544A1 (en) * 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a hydrocortisone acetate as a corticosteroid, and clotrimazole as an antifungal agent, and a process to make it
PL2734216T3 (pl) * 2011-07-20 2018-12-31 Mediwound, Ltd. Ekstrakt proteolityczny z bromelainy do leczenia schorzeń tkanki łącznej

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358500A1 (en) * 1988-09-08 1990-03-14 The Public Health Laboratory Service Board Method and composition for the treatment and prevention of viral infections
WO1995023614A1 (en) * 1994-03-01 1995-09-08 E.R. Squibb & Sons, Inc. Enzymatic debridement compositions and methods
US5560910A (en) * 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US20040151716A1 (en) * 2003-02-03 2004-08-05 Hamer Richard A. Material and method for treating microbial mediated dermatological conditions
US20070275045A1 (en) * 2006-02-28 2007-11-29 Evans Robin D Composition for the treatment of warts and molluscum contagiosum
US20110243918A1 (en) * 2009-08-25 2011-10-06 Thornton Joseph P Topical medication for the treatment of hemorrhoids and method of use
US20110182874A1 (en) * 2009-11-23 2011-07-28 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NGUYEN UYEN T ET AL: "DNase I and proteinase K impair Listeria monocytogenes biofilm formation and induce dispersal of pre-existing biofilms", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, ELSEVIER BV, NL, vol. 187, 4 July 2014 (2014-07-04), pages 26 - 32, XP029013073, ISSN: 0168-1605, DOI: 10.1016/J.IJFOODMICRO.2014.06.025 *
PAVAN RAJENDRA ET AL: "Properties and therapeutic application of bromelain: a review.", BIOTECHNOLOGY RESEARCH INTERNATIONAL 2012, vol. 2012, 976203, 2012, pages 1 - 6, XP002753417, ISSN: 2090-3146, DOI: 10.1155/2012/976203 *
SILVA JULIANA ET AL: "Antifungal activity of bromelain in Candida pre-formed biofilms", ANTIMICROBIAL RESEARCH - ICAR2012, LISBON (PORTUGAL) 21-23 NOVEMBER 2012, THE BOOK OF ABSTRACTS: PAGE 272, November 2012 (2012-11-01), pages 272, XP055244889 *

Also Published As

Publication number Publication date
EP3210619A2 (en) 2017-08-30
US20170304411A1 (en) 2017-10-26
WO2016063265A2 (pt) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2015066647A3 (en) Ionic liquids for transdermal drug delivery
CA3006294A1 (en) Combinations of rapamycin and metformin for the treatment of joint and skin diseases
WO2014186742A3 (en) Anhydrous hydrogel composition
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
EA201391823A1 (ru) Высушенные распылением штаммы/клетки лактобактерий и их применение против helicobacter pylori
CO2022007953A2 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
BR112015005339A8 (pt) uso de óleo de semente de fruta milagrosa como um ingrediente ativo
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2016057413A3 (en) Inhibitors of lysine gingipain
JP2014520892A5 (pt)
WO2013092457A3 (de) Wirkstoffkombinationen aus einer oder mehreren carbonsäuren, insbesondere hydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen hydroxamsäure sowie kosmetische oder dermatologische zubereitungen, solche wirkstoffkombinationen enthaltend
WO2016063265A3 (pt) Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
MA36538B1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
WO2007082864A3 (en) Use of chavicol as an antiseptic
BR112014016804A2 (pt) composições, métodos de uso e métodos de tratamento
WO2017142368A3 (ko) 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물
PH12020550029A1 (en) Topical formulations of chloroprocaine
WO2014137231A3 (en) Totarol extract formulations and uses thereof
WO2021081110A3 (en) Peptides and use thereof
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
WO2012083397A8 (en) Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15805257

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15521403

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015805257

Country of ref document: EP